Navigation Links
Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinson's Disease

Effort utilizes Phreesia's automated patient check-in system to enable

better management of medication wear-off

NEW YORK, April 15 /PRNewswire/ -- Phreesia, Inc., the Patient Check-In Company, has announced that it will integrate a new screening tool developed by researchers at Duke University Medical Center into its electronic patient intake process, thereby potentially enhancing the ability of doctors to identify and manage the debilitating symptoms of Parkinson's disease.

(Logo: )

Affecting about one million people in the United States, Parkinson's disease is a degenerative disorder that impairs nerve cells causing patients to experience tremors, slowness of movement, muscle rigidity, and difficulty with balance. Drug therapy is highly effective, but within 2 years of initiating treatment up to 50% of patients can experience a decrease in drug efficacy, a phenomenon that is referred to as "wearing-off".

"Recognition of wearing-off and under treatment in Parkinson's disease patients is a major problem", said Mark Stacy, MD, Director of the Movement Disorders Center at Duke University's School of Medicine. Research has shown that nearly half of all patients that report wearing-off are not identified in a routine clinical exam. To help address this inconsistency, Phreesia will automate the "Wearing-Off Questionnaire-9" (WOQ-9), a highly sensitive screening tool specifically designed by researchers at Duke to identify these symptoms in the clinical setting.

Frequently, paper screening tools are cumbersome to implement clinically. As part of Phreesia's electronic patient intake system patients with Parkinson's disease will answer questions from the WOQ-9 and the results will be made available to their physician prior to starting the clinical exam. By enabling physicians nationwide to automate the WOQ-9 in their waiting room a higher identification rate of wearing-off is anticipated, ideally resulting in subsequent treatment and potentially better patient outcomes.

Physicians who use Phreesia will have the option to seamlessly integrate the WOQ-9 into their existing intake process and evaluate responses at both the patient and practice level. "This is Phreesia at its best -- leveraging evidence-based clinical assessment tools to improve patient care", said Chaim Indig, CEO of Phreesia. The implementation of the WOQ-9 is one of many clinical initiatives that Phreesia is developing for physicians who use their electronic patient check-in system.

About Phreesia:

Phreesia is the patient check-in company. Phreesia automates patient check-in and delivers fully interactive content direct-to-patients, designed to interface with physicians' existing and future technology. Replacing the outdated patient clipboard with a free wireless touch-screen and swipe-card enabled PhreesiaPad significantly improves the patient experience. Phreesia is committed to the ideals of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Phreesia is backed by premier venture capital firms and draws on the expertise of a leading Medical Advisory Board.

SOURCE Phreesia, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
4. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
5. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
6. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
7. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
8. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
9. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
10. Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
11. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
Post Your Comments:
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... has always been a country of choice for global multi-center ... Europe in 2015 were tested in phase II-III clinical ... has always been a country of choice for global multi-center phase III ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for the care management and population health arenas, is pleased to announce that ... cost containment services, has successfully implemented the ACUITY Complete Care™ Management to back ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash Moradzadeh ... Man for 2015. , Angeleno Magazine is a division of Modern Luxury, ... 1994, Modern Luxury includes more than 50 magazine titles across 15 major markets. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced today that it has officially launched a sleek, mobile-ready and user-centric redesigned ... his company’s new website clearly outlines the benefits that its SEO services provide ...
Breaking Medicine News(10 mins):